Gene · 64783
Papers2,224
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 2,224
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Development of an m6A-Related lncRNAs Signature Predicts Tumor Stemness and Prognosis for Low-Grade Glioma Patients. | Stem Cells Int | 2024 | 38229597 | PubTator, text mining | PubMed |
| The pyroptosis-related signature predicts prognosis and influences the tumor immune microenvironment in dedifferentiated liposarcoma. | Open Med (Wars) | 2024 | 38221934 | PubTator, text mining | PubMed |
| Development and validation of epigenetic modification-related signals for the diagnosis and prognosis of colorectal cancer. | BMC Genomics | 2024 | 38212708 | PubTator, text mining | PubMed |
| Characterization of m6A methylation modifications in gastric cancer. | Aging (Albany NY) | 2024 | 38206646 | PubTator, text mining | PubMed |
| N6-methyladenosine methylation in ophthalmic diseases: From mechanisms to potential applications. | Heliyon | 2024 | 38192819 | PubTator, text mining | PubMed |
| N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. | Mol Cancer | 2024 | 38184597 | PubTator, text mining | PubMed |
| Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation. | Eur J Med Res | 2024 | 38173044 | PubTator, text mining | PubMed |
| Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment. | BMC Urol | 2024 | 38172792 | PubTator, text mining | PubMed |
| M6A plays a potential role in carotid atherosclerosis by modulating immune cell modification and regulating aging-related genes. | Sci Rep | 2024 | 38168909 | PubTator, text mining | PubMed |
| The role of the methyltransferase METTL3 in prostate cancer: a potential therapeutic target. | BMC Cancer | 2024 | 38166703 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A reader YTHDF2 prognosis, immune infiltration, and related regulatory networks in hepatocellular carcinoma. | Heliyon | 2024 | 38163150 | PubTator, text mining | PubMed |
| Targeting key RNA methylation enzymes to improve the outcome of colorectal cancer chemotherapy (Review). | Int J Oncol | 2024 | 38131226 | PubTator, text mining | PubMed |
| BIRC5 facilitates cisplatin-chemoresistance in a m6A-dependent manner in ovarian cancer. | Cancer Med | 2024 | 38112021 | PubTator, text mining | PubMed |
| Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response. | Noncoding RNA Res | 2024 | 38075202 | PubTator, text mining | PubMed |
| m6A-related lncRNAs as potential biomarkers and the lncRNA ELFN1-AS1/miR-182-5p/BCL-2 regulatory axis in diffuse large B-cell lymphoma. | J Cell Mol Med | 2024 | 38037859 | PubTator, text mining | PubMed |
| A novel HPV16 splicing enhancer critical for viral oncogene expression and cell immortalization. | Nucleic Acids Res | 2024 | 37994701 | PubTator, text mining | PubMed |
| Interconnections between m6A RNA modification, RNA structure, and protein-RNA complex assembly. | Life Sci Alliance | 2024 | 37935465 | PubTator, text mining | PubMed |
| Decoding m6A mRNA methylation by reader proteins in liver diseases. | Genes Dis | 2024 | 37692496 | PubTator, text mining | PubMed |
| The essential roles of m6A modification in osteogenesis and common bone diseases. | Genes Dis | 2024 | 37588215 | PubTator, text mining | PubMed |
| The role of m6A RNA methylation in autoimmune diseases: Novel therapeutic opportunities. | Genes Dis | 2024 | 37588214 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/64783/papers?page=9